scholarly journals Correction to: Superselective intra-arterial chemoradiotherapy using altered blood flow compared to conventional systemic chemoradiotherapy for locally advanced oral squamous cell carcinoma: a single-center retrospective study

2021 ◽  
Author(s):  
Koichi Masuda ◽  
Shinji Yamazoe ◽  
Akira Baba ◽  
Takuji Mogami ◽  
Satoru Ogane ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Blood Flow ◽  
Retrospective Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Single Center ◽  
Altered Blood

scholarly journals FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study

Tumor Biology ◽  
2017 ◽  
Vol 39 (10) ◽  
pp. 101042831773177 ◽  
Author(s):  
Hidetaka Arita ◽  
Masashi Nagata ◽  
Ryoji Yoshida ◽  
Yuichiro Matsuoka ◽  
Akiyuki Hirosue ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Retrospective Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Single Center

P-97 The impact of tobacco smoking on survival for patients with oral squamous cell carcinoma: a population-based retrospective study

Oral Oncology ◽  
2021 ◽  
Vol 118 ◽  
pp. 12
Author(s):  
Amanda Oester Andersen ◽  
Jakob Schmidt Jensen ◽  
Kathrine Kronberg Jakobsen ◽  
Helene Stampe ◽  
Kristoffer Juul Nielsen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Retrospective Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tobacco Smoking ◽  
Population Based ◽  
The Impact

P-96 The impact of tobacco smoking on survival for patients with oral squamous cell carcinoma: a population-based retrospective study

Oral Oncology ◽  
2021 ◽  
Vol 118 ◽  
pp. 11
Author(s):  
Amanda Oester Andersen ◽  
Jakob Schmidt Jensen ◽  
Kathrine Kronberg Jakobsen ◽  
Helene Stampe ◽  
Kristoffer Juul Nielsen ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Retrospective Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tobacco Smoking ◽  
Population Based ◽  
The Impact

scholarly journals Oral squamous cell carcinoma: a clinicopathological study on 194 cases in northeastern Brazil. A cross-sectional retrospective study

2018 ◽  
Vol 136 (2) ◽  
pp. 165-169 ◽  
Author(s):  
Amanda Almeida Leite ◽  
Augusto César Leal da Silva Leonel ◽  
Jurema Freire Lisboa de Castro ◽  
Elaine Judite de Amorim Carvalho ◽  
Pablo Agustin Vargas ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Retrospective Study ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Northeastern Brazil ◽  
Cross Sectional ◽  
Clinicopathological Study

Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6052-6052
Author(s):  
Lai-Ping Zhong ◽  
Wu-tong Ju ◽  
Rong-hui Xia ◽  
Qi Zhu ◽  
Guopei Zhu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Induction Therapy ◽  
Clinical Stage ◽  
Locally Advanced ◽  
Radiological Evaluation ◽  
Primary Tumors ◽  
Viable Tumor

6052 Background: In patients with locally advanced oral squamous cell carcinoma (LAOSCC), major pathologic response (MPR) to induction therapy may translate into improved survival. The induction therapy using chemo-free drugs, such as the combination of anti-PD1 and anti-VEGFR drugs, has not been well issued in LAOSCC. Methods: A prospective single arm trial (NCT04393506) has been performed to evaluate the induction therapy of anti-PD1 and anti-VEGFR protocol in LAOSCC patients at clinical stage III and IVA. The patients received three cycles of intravenous Camrelizumab (PD-1 antibody, 200mg) on d1, d15, d29; and oral Apatinib (anti-VEGFR inhibitor, 250mg) daily, initiating on d1, ending on the 5th day before surgery. Radical surgery was planned on d42-d45. Post-operative radiotherapy was planned within 1.5 months after surgery, based on clinical and pathological stage. The primary endpoints were MPR and safety; primary tumors were assessed for the percentage of residual viable tumor that was identified on HE staining, and tumors with no more than 10% viable tumor cells were considered as MPR. This study has been approved by institutional ethics committee at Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Results: From April to December 2020, 21 patients were enrolled in this trial, and one patient withdraw from the trial at the beginning of treatment. The induction therapy was well-tolerated with no grade 3-4 toxicity or serve induction therapy-related AEs. One patient required surgery delay for 7 days due to unexplainable cTnI elevation. One patient put off Camrelizumab for 14 days due to grade 2 thrombocytopenia. One patient suspended Apatinib for 21 days due to grade 2 Hyperbilirubinemia. The induction therapy did not effect on the subsequent standard treatment. MPR rate was 40% (8/20), including 5% (1/20) pCR. Radiological evaluation of response to induction therapy showed 3 PR, 10 SD, 5 PD and 2 NA. Weak correlation was found between pathologic and radiological evaluation on induction therapy. Combined positive score (CPS) of PD-L1 expression in biopsy was evaluated in 19 patients; all 4 patients with CPS≥ 20 had MPR, 3 out of 11 patients with 1≤CPS < 20 had MPR, and 1 out of 4 patients with CPS < 1 had MPR. Conclusions: The chemo-free protocol of induction therapy using Camrelizumab and Apatinib is safe and well-tolerated for the patients with LAOSCC. The MPR rate is much higher using the anti-PD1 and anti-VEGFR protocol than the traditional induction chemotherapy protocol in LAOSCC. Clinical trial information: NCT04393506.

Sign in / Sign up

Export Citation Format

Share Document